TABLE 7.
Clinical response at the end of treatment and 7 days after the end of treatment in patients with febrile neutropenia
| Efficacy outcome | No. (%) of patients
|
|||||||
|---|---|---|---|---|---|---|---|---|
| Group 1 (200 mg q.i.d./ 400 mg b.i.d.)
|
Group 2 (400 mg q.i.d./ 600 mg b.i.d.)
|
Group 3 (800 mg b.i.d./ 800 mg q.d.)
|
Total
|
|||||
| Efficacy evaluable | All randomized | Efficacy evaluable | All randomized | Efficacy evaluable | All randomized | Efficacy evaluable | All randomized | |
| End of treatment | ||||||||
| Total | 19 | 23 | 18 | 21 | 16 | 22 | 53 | 66 |
| Success | 14 (74) | 14 (61) | 14 (78) | 14 (67) | 13 (81) | 14 (64) | 41 (77) | 42 (64) |
| Failure | 5 (26) | 9 (39) | 4 (23) | 7 (33) | 3 (19) | 8 (36) | 12 (23) | 24 (36) |
| Clinical failure | 5 (26) | 6 (26) | 3 (17) | 4 (19) | 2 (13) | 2 (9) | 10 (19) | 12 (18) |
| Missing | 0 | 3 (13) | 1 (6) | 3 (14) | 1 (6) | 6 (27) | 2 (4) | 12 (18) |
| Posttreatment plus 7 daysa | ||||||||
| Total | 17 | 17 | 13 | 47 | ||||
| Success | 13 (76) | 14 (82) | 11 (85) | 38 (81) | ||||
| Failure | 4 (24) | 3 (18) | 2 (15) | 9 (19) | ||||
| Clinical failure | 4 (24) | 2 (12) | 2 (15) | 8 (17) | ||||
| Missing | 0 | 1 (6) | 0 | 1 (2) | ||||
a
Data for clinical efficacy 7 days after end of treatment were not collected for all randomized patients.